Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
ConclusionsResults suggest that treatment intensification is often delayed despite consistently poor glycaemic control for more than 12 months, contrary to treatment guideline recommendations. Findings from this study highlight that some T2DM patients may benefit from more rapid treatment intensification, which could improve glycaemic control and reduce the risk for many short- and long-term health complications.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Study